Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512855 | 1.00 | KEAP1 (0.47) | KEAP1NFE2L2GLO1SLC40A1GAA | |
| SCHEMBL29969263 | 0.89 | CACNA1B (0.48) | CACNA1BCACNA1HFFAR4HDAC3HDAC4 | |
| SCHEMBL21513746 | 0.89 | CACNA1B (0.48) | CACNA1BCACNA1HFFAR4HDAC3HDAC4 | |
| SCHEMBL29970032 | 0.88 | CACNA1B (0.51) | SLC40A1CACNA1BCACNA1H | |
| SCHEMBL21513456 | 0.85 | SLC40A1 (0.44) | KEAP1NFE2L2GLO1SLC40A1CACNA1B | |
| SCHEMBL29969232 | 0.85 | SLC40A1 (0.44) | KEAP1NFE2L2GLO1SLC40A1CACNA1B | |
| SCHEMBL29969654 | 0.85 | CACNA1B (0.47) | SLC40A1CACNA1BCACNA1HHDAC3HDAC4 | |
| SCHEMBL26130327 | 0.85 | CACNA1B (0.47) | SLC40A1CACNA1BCACNA1HHDAC3HDAC4 | |
| SCHEMBL21513747 | 0.85 | CACNA1H (0.47) | SLC40A1GAACACNA1BCACNA1HPGR | |
| SCHEMBL21513752 | 0.85 | CACNA1B (0.48) | GLO1SLC40A1CACNA1BCACNA1HTRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | KEAP1 1063/4885NFE2L2 838/4885GLO1 4474/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | KEAP1 1063/4885NFE2L2 838/4885GLO1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.